ContraFect Logo
US2123263004
A2PZKK
CFRX

ContraFect

Loading quotes...

Forecast

Buy
  2
Hold
  3
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, ContraFect had revenue of €0 and net profit of -€60.74M
(EUR) 2022
YoY
Revenue 0 -
Gross profit 0 -
Net profit -60.74M 1,108.45%
EBITDA -60.09M 46,267.53%

Fundamentals

Metric Value
Market capitalization
€0
52-week high/low
€8.75 - €0.0227
Dividends No
Beta
0.29
P/E ratio
0.00
PEG ratio
0.00
P/B ratio
0.00
P/S ratio
0.00

Company profile

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Name
ContraFect
CEO
Michael Messinger CPA
Headquarters Yonkers, ny
USA
Website
Sector
Materials
Industry
Chemicals
IPO
09/12/2014
Employees 23

Ticker symbols

Exchange Symbol
NASDAQ
CFRX
Frankfurt
22R1.F
München
22R1.MU
🍪

Parqet  uses cookies. Learn more